BIOFRONTERA AG (BFRA)

ADR

2.67  -0.28 (-9.49%)

Fundamental Rating

1

BFRA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. BFRA has a bad profitability rating. Also its financial health evaluation is rather negative. BFRA is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

BFRA had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -22.64%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -42.23%
PM (TTM) -55.98%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

BFRA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, BFRA has a worse debt to assets ratio.

2.2 Solvency

BFRA has an Altman-Z score of -2.09. This is a bad value and indicates that BFRA is not financially healthy and even has some risk of bankruptcy.
BFRA has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -2.09
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

BFRA has a Current Ratio of 1.26. This is a normal value and indicates that BFRA is financially healthy and should not expect problems in meeting its short term obligations.
BFRA has a Quick Ratio of 1.13. This is a normal value and indicates that BFRA is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.13

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.53% over the past year.
Looking at the last year, BFRA shows a very negative growth in Revenue. The Revenue has decreased by -15.27% in the last year.
The Revenue has been growing by 48.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q16.67%
Revenue 1Y (TTM)-15.27%
Revenue growth 3Y36.15%
Revenue growth 5Y48.96%
Revenue growth Q2Q14.13%

3.2 Future

Based on estimates for the next years, BFRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.07% on average per year.
Based on estimates for the next years, BFRA will show a small growth in Revenue. The Revenue will grow by 6.84% on average per year.
EPS Next Y-137.77%
EPS Next 2Y-19.62%
EPS Next 3Y24.2%
EPS Next 5Y12.07%
Revenue Next Year-5.25%
Revenue Next 2Y8.35%
Revenue Next 3Y4.65%
Revenue Next 5Y6.84%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BFRA. In the last year negative earnings were reported.
Also next year BFRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -14.91

4.3 Compensation for Growth

BFRA's earnings are expected to grow with 24.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.62%
EPS Next 3Y24.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BFRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA AG

NASDAQ:BFRA (3/4/2022, 7:19:41 PM)

2.67

-0.28 (-9.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap151.44M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.64%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -42.23%
PM (TTM) -55.98%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.26
Quick Ratio 1.13
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-137.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.27%
Revenue growth 3Y36.15%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y